Skip to main content
OpenTrials
Completed

NCT Number: NCT03375008

Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)

1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2. To develop non-invasive diagnosis tool using multiparametric Magnetic resonance(MR) imaging for nonalcoholic steatohepatitis(NASH)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nonalcoholic Steatohepatitis Digestive System Diseases Fatty Liver Liver Diseases Non-alcoholic Fatty Liver Disease

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Korea University Guro Hospital

Seoul, Guro-gu, 08308, South Korea

About this study

Nonalcoholic steatohepatitis(NASH) is a severe form of nonalcoholic fatty liver disease(NAFLD). The causes are known to be associated with metabolic diseases such as obesity, insulin resistance type 2 diabetes, and hypercholesterolemia. Histologically, it is characterized by steatosis, hepatocellular injury, and inflammation and fibrosis of the liver parenchyma. Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma(HCC) may develop even in patients without viral hepatitis, therefore there have been much interest and many researches in causation and diagnosis for nonalcoholic steatohepatitis(NASH).

Liver biopsy remains the gold standard for the diagnosis of nonalcoholic fatty liver disease(NAFLD) and is the only reliable method for differentiating nonalcoholic steatohepatitis(NASH) from simple steatosis. However, liver biopsy has several drawbacks, including invasiveness, potential complications such as excessive bleeding and death, sampling error, and inter- and intra-observer variability.

Magnetic resonance(MR) imaging has been used as a multiparametric imaging tool with which to evaluate steatosis by chemical shift imaging andm magnetic resonance(MR) spectroscopy, and fibrosis by magnetic resonance(MR) elastography and T1 mapping. To the best of our knowledge, there is no accurate imaging diagnostic tool for nonalcoholic steatohepatitis(NASH), therefore the investigators aimed to develop non-invasive imaging diagnostic model using multiparametric magnetic resonance imager(MRI).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >19 years age
  • Patients who had elevated aspartate transaminase(AST)/alanine transaminase(ALT) and fatty liver on abdominal ultrasonography
  • Patients who are clinically suspected to have nonalcoholic steatohepatitis(NASH)
  • Clinically suspected nonalcoholic steatohepatitis(NASH): >40 years age, metabolic syndrome, fibrosis on transient elastography(TE, Fibroscan), or elevated Fibrosis-4(FIB-4), Aspartate aminotransferase-to-platelet ratio index(APRI), nonalcoholic fatty liver disease fibrosis score(NFS) on blood tests
  • Patients who underwent (<6 months) or will undergo US-guided liver biopsy

Exclusion criteria

  • Chronic liver disease other than nonalcoholic fatty liver disease(NAFLD) (chronic hepatitis B or C, autoimmune hepatitis, primary biliary sclerosis)
  • Alcohol abuse (men, >140g/week; women, >70g/week)
  • Fatty liver due to medication
  • Contraindication to magnetic resonance imager(MRI)
  • Hepatocellular carcinoma
  • Pregnancy

Treatment and study plan

Imaging diagnostic and biopsy

Diagnostic Test

Liver biopsy and MRI scan

Primary outcomes

  1. Radiologic Diagnosis & Criteria of nonalcoholic steatohepatitis(NASH)

    Time frame: up to 23 month

    Development of non-invasive magnetic resonance imaging diagnostic model for NASH using linear regression analysis

    • Linear regression analysis using three magnetic resonance(MR) parameters 1) Fat signal fraction measured on MR spectroscopy (unit: %) 2) Liver stiffness measured on MR elastography (unit: kPa) 3) T1 relaxation time measured on T1 mapping (unit: msec) → Development of linear equation for NAFLD activity score (NAS) and Steatosis, Activity, Fibrosis (SAF) score
    • Fitting of observed values (NAS, SAF score) and predicted values (NAS, SAF score) → Obtaining R square (R2) (Unit: none)

Secondary outcomes

  1. Fat imaging : Fat signal fraction measured on magnetic resonance(MR) spectroscopy

    Time frame: During scanning, up to 15 seconds

    • Fat signal fraction measured on magnetic resonance(MR) spectroscopy
    • high speed T2-corrected multi-echo (HISTO) MR spectroscopic technique
    • multiple short echo time : correction of T2 bias
    • long repetition time: correction of T1 bias
    • 15 x 15 x 15-mm square-shaped region-of-interest(ROI) → Right hepatic lobe
    • 3 times measurement → mean value was used as a representative value
    • unit: percentage (%)
    • Receiver operating characteristic (ROC) curve analysis for steatosis grade (0-3) → Obtaining cut-off values of each steatosis grade and area under the curve (AUC)

  2. Fibrosis imaging(1) : Liver stiffness measured on magnetic resonance elastography(MRE)

    Time frame: During scanning, up to 20 seconds

    • Magnetic resonance elastography(MRE)
    • 60 Hz acoustic wave
    • Four slices were obtained for each magnetic resonance elastography(MRE) examination
    • Stiffness maps (elastograms) for each magnetic resonance elastography(MRE) slices were automatically generated
    • free-hand region-of-interest (ROI) on the right hepatic lobe
    • 5 times measurement → mean value was used as a representative value
    • unit: kilopascal (kPa)
    • Receiver operating characteristic (ROC) curve analysis for fibrosis grade (0-4) → Obtaining cut-off values of each fibrosis grade and area under the curve (AUC)

  3. Fibrosis imaging(2) : T1 relaxation time measured on T1 mapping

    Time frame: During scanning, up to 20 seconds

    • T1 mapping
    • Shortened Modified Look Locker Inversion (shMOLLI) recovery sequence
    • Four slices were obtained for each T1 map
    • Oval-shaped region-of-interest (ROI) in the right hepatic lobe
    • 5 times measurement → mean value was used as a representative value
    • unit: millisecond (msec)
    • Receiver operating characteristic (ROC) curve analysis for ballooning (0-2), lobular inflammation (0-3), fibrosis grade (0-4) → Obtaining cut-off values of each grade and area under the curve (AUC)

  4. Histologic interpretation(1) : Nonalcoholic fatty liver disease activity score (NAS)

    Time frame: Up to a week

    • the sum of each histological component semiquantitatively evaluated as follows: steatosis (0-3), ballooning (0-2), and lobular inflammation (0-3)
    • NAS 0-2: not considered steatohepatitis
    • NAS 3-4: possible steatohepatitis 4/ NAS ≥5: definite steatohepatitis

  5. Histologic interpretation(1) : Steatosis, Activity, Fibrosis (SAF) score

    Time frame: Up to a week

    • steatosis (0-3), ballooning degeneration (0-2), lobular inflammation (0-2), and fibrosis (0-4).
    • Nonalcoholic steatohepatitis(NASH): when steatosis is present and when both features of activity (ballooning and lobular inflammation) display at least grade 1
    • Unit: None

Sponsors and collaborators

Lead sponsor

Korea University Guro Hospital

Other

Registry information

Official study title

Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Dec 15, 2017
Registry last updated
May 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.